Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle elicited by exposure to volatile anesthetics and depolarizing muscle relaxants. The disorder is well recognized in humans and pigs, although a number of definite episodes have also been reported in dogs. When given above mentioned agents, MH-susceptible (MHS) dogs show tachycardia, hyperthermia, elevated carbon dioxide production, and death, if the anesthetic is not discontinued. Specific interventions, including use of the calcium release channel antagonist dantrolene, are efficacious in reversing signs of the canine syndrome. In most reports of MH in dogs, metabolic acidosis is moderate and muscle rigidity is minimal, in contrast to the severity of both in the swine or human condition.
Inheritance: autosomal dominant- read more
Mutation: RYR1 gene
Genetic test: Disease or carrier can be identified by genetic testing at any age. The PCR method used for testing is extremely accurate and allows complete differentiation between affected animals, carriers and healthy dogs.
Disease control: read more
Affected breeds: all breeds
Sample: EDTA whole blood (1.0 ml) or buccal swabs. Detailed information about sampling can be found here.